Curative Effects Observation of Capecitabine and Hessaitin Combined with Whole Brain Radiotherapy for Treatment The HER2 Positive Breast Cancer with Brain Metastasis_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 YANGJian , NARi-su , GuoChun-liang

Department of Hepatobiliary Surgery, Affiliated Hospital of Armed Police Logistics Institute Tianjin 300162, china;

Corresponding?author：

YANGJian, Email: yangjianzg@126.com

Keywords：

HER 2 positive brest cancer; Capecitabine; Trastuzumab; Whole brain radiotherapy; Brain metastasis; Curative effect

DOI：

10.7507/1007-9424.20150118

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the curative effects of capecitabine and hessaitin combined with whole brain radiotherapy for treatment the HER2 positive breast cancer with brain metastasis. Methods The clinical data of 60 cases HER2-positive breast cancer patients with brain metastasis in our hospital in January 2004 to January 2012 were retrospectively analyzed.The 32 cases of observe group were treated by using capecitabine and herceptin combined with whole brain radiotherapy, and the 28 cases of control group were treated by using capecitabine and cisplatin combined with whole brain radiotherapy.The disease control rate, toxicity rate, and survival rate were evaluated. Results Compared with the control group, the disease control rate, toxicity rate, and survival rate were all better in observe group (P < 0.05). Conclusion The capecitabine and hessaitin combined with whole brain radiotherapy for treating patients with HER 2 positive brest cancer transferred to brain are effect and safe.

Citation： YANGJian, NARi-su, GuoChun-liang. Curative Effects Observation of Capecitabine and Hessaitin Combined with Whole Brain Radiotherapy for Treatment The HER2 Positive Breast Cancer with Brain Metastasis. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(4): 447-450. doi: 10.7507/1007-9424.20150118 Copy

1.	王丹.多西他賽聯合順鉑治療乳腺癌的護理.藥物與人, 2014, 27(2):80.
2.	Shan M, Wang X, Sun G, et al.A retrospective study of the clinical differences of Uygur breast cancer patients compared to Han breast cancer patients in the Xinjiang region of China.Int J Clin Exp Med, 2014, 7(10):3482-3490.
3.	徐金明, 黎可, 陳軒, 等.曲妥珠單抗對HER2陽性乳腺癌患者術后輔助治療的臨床觀察.重慶醫學, 2013, 42(9):1025-1026.
4.	Li XJ, Zha QB, Xu XY, et al.Lack of prognostic value of human epidermal growth factor-like receptor 2 status in inflammatory breast cancer (IBC):a meta-analysis.Asian Pac J Cancer Prev, 2014, 15(22):9615-9619.
5.	Chiba A, Shimizu S, Yoshida A, et al.Eficacy and toxicity of lapatinib plus eapecitabine therapy in HER2-positive metastatic breast cancer.Gala To Kagaku Ryoho, 2012, 39(11):1675-1679.
6.	Niikura N, Saji S, Tokuda Y, et al.Brain metastases in breast cancer.Jpn J Clin Oncol, 2014, 44(12):1133-1140.
7.	高會全, 馬學真, 董桂芝, 等.卡培他濱聯合放療治療乳腺癌腦轉移療效分析.中華腦科疾病與康復雜志, 2013, 3(2):29-31.
8.	Lam SW, de Groot SM, Honkoop AH, et al.Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer:a multicentre, open-label, randomised phase 2 trial.Eur J Cancer, 2014, 50(18):3077-3088.
9.	李晶, 歐陽取長, 劉莉萍.吉西他濱聯合曲妥珠單抗或順鉑治療HER2陽性晚期乳腺癌的療效觀察.中國醫師雜志, 2012, 14(11):1547-1549.
10.	Sasaki T.New guidelines to evaluate the response to treatment "RECIST".Gan To Kagaku Ryoho, 2000, 27(14):2179-2184.
11.	Miller AB, Hoogstraten B, Staquet M, et al.Reporting results of cancer treatment.Cancer, 1981, 47(1):207-214.
12.	林琳, 洪熠, 陳侃, 等.乳腺癌腦轉移全腦放療后綜合治療的療效觀察.臨床腫瘤學雜志, 2012, 17(11):1012-1015.
13.	Niwińska A, Murawska M, Pogoda K.Breast cancer brain metas-tases:differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT).Ann Oncol, 2010, 21(5):942-948.
14.	Miolo G, Muraro E, Martorelli D, et al.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.BMC Cancer, 2014, 14(1):954.
15.	DE Felice F, Musio D, Cassese R, et al.Radiotherapeutic treatment approaches for brain metastases.Anticancer Res, 2014, 34(12):6913-6918.
16.	Dimri K, Trehan R, Pandey AK, et al.Long term survival after whole brain radiotherapy for brain metastasis in follicular dendritic cell sarcoma.Indian J Cancer, 2014, 51(3):395-396.
17.	Hameed H, Cassidy J.Use of capecitabine in management of early colon cancer.Cancer Manag Res, 2011, 3:295-299.
18.	Tolaney S1, Burris H, Gartner E, et al.PhaseⅠ/Ⅱstudy of pilara-lisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.Breast Cancer Res Treat, 2015, 149(1):151-161.
19.	謝聯斌, 謝莉, 袁麗方.多西紫杉醇聯合卡培他濱治療蒽環類耐藥晚期三陰性乳腺癌的臨床觀察.中華乳腺病雜志, 2012, 4(3):339-340.
20.	Sotelo MJ, García-Sáenz JA, Manso L, et al.Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.J Cancer Res Ther, 2014, 10(4):967-972.
21.	Tolaney SM, Barry WT, Dang CT, et al.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.N Engl J Med, 2015, 372(2):134-141.
22.	Aboutorabi A, Hadian M, Ghaderi H, et al.Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.Glob J Health Sci, 2014, 7(1):37868.
23.	陳小松, 沈坤煒.曲妥珠單抗在HER2陽性乳腺癌治療中的共識與爭議.外科理論與實踐, 2011, 16(6):601-602.
24.	Church DN, Modgil R, Guglani S, et al.Extended survival in women with brain metastases from HER-2 overexpressing breast cancer.Am J Clin Oncol, 2008, 31(3):250-254.
25.	Eichler AF, Kuter I, Ryan P, et al.Survival in patients with brain metastases from breast cancer:the importance of HER-2 status.Cancer, 2008, 112(11):2359-2367.

1. 王丹.多西他賽聯合順鉑治療乳腺癌的護理.藥物與人, 2014, 27(2):80.
2. Shan M, Wang X, Sun G, et al.A retrospective study of the clinical differences of Uygur breast cancer patients compared to Han breast cancer patients in the Xinjiang region of China.Int J Clin Exp Med, 2014, 7(10):3482-3490.
3. 徐金明, 黎可, 陳軒, 等.曲妥珠單抗對HER2陽性乳腺癌患者術后輔助治療的臨床觀察.重慶醫學, 2013, 42(9):1025-1026.
4. Li XJ, Zha QB, Xu XY, et al.Lack of prognostic value of human epidermal growth factor-like receptor 2 status in inflammatory breast cancer (IBC):a meta-analysis.Asian Pac J Cancer Prev, 2014, 15(22):9615-9619.
5. Chiba A, Shimizu S, Yoshida A, et al.Eficacy and toxicity of lapatinib plus eapecitabine therapy in HER2-positive metastatic breast cancer.Gala To Kagaku Ryoho, 2012, 39(11):1675-1679.
6. Niikura N, Saji S, Tokuda Y, et al.Brain metastases in breast cancer.Jpn J Clin Oncol, 2014, 44(12):1133-1140.
7. 高會全, 馬學真, 董桂芝, 等.卡培他濱聯合放療治療乳腺癌腦轉移療效分析.中華腦科疾病與康復雜志, 2013, 3(2):29-31.
8. Lam SW, de Groot SM, Honkoop AH, et al.Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer:a multicentre, open-label, randomised phase 2 trial.Eur J Cancer, 2014, 50(18):3077-3088.
9. 李晶, 歐陽取長, 劉莉萍.吉西他濱聯合曲妥珠單抗或順鉑治療HER2陽性晚期乳腺癌的療效觀察.中國醫師雜志, 2012, 14(11):1547-1549.
10. Sasaki T.New guidelines to evaluate the response to treatment "RECIST".Gan To Kagaku Ryoho, 2000, 27(14):2179-2184.
11. Miller AB, Hoogstraten B, Staquet M, et al.Reporting results of cancer treatment.Cancer, 1981, 47(1):207-214.
12. 林琳, 洪熠, 陳侃, 等.乳腺癌腦轉移全腦放療后綜合治療的療效觀察.臨床腫瘤學雜志, 2012, 17(11):1012-1015.
13. Niwińska A, Murawska M, Pogoda K.Breast cancer brain metas-tases:differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole brain radiotherapy (WBRT).Ann Oncol, 2010, 21(5):942-948.
14. Miolo G, Muraro E, Martorelli D, et al.Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.BMC Cancer, 2014, 14(1):954.
15. DE Felice F, Musio D, Cassese R, et al.Radiotherapeutic treatment approaches for brain metastases.Anticancer Res, 2014, 34(12):6913-6918.
16. Dimri K, Trehan R, Pandey AK, et al.Long term survival after whole brain radiotherapy for brain metastasis in follicular dendritic cell sarcoma.Indian J Cancer, 2014, 51(3):395-396.
17. Hameed H, Cassidy J.Use of capecitabine in management of early colon cancer.Cancer Manag Res, 2011, 3:295-299.
18. Tolaney S1, Burris H, Gartner E, et al.PhaseⅠ/Ⅱstudy of pilara-lisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.Breast Cancer Res Treat, 2015, 149(1):151-161.
19. 謝聯斌, 謝莉, 袁麗方.多西紫杉醇聯合卡培他濱治療蒽環類耐藥晚期三陰性乳腺癌的臨床觀察.中華乳腺病雜志, 2012, 4(3):339-340.
20. Sotelo MJ, García-Sáenz JA, Manso L, et al.Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer.J Cancer Res Ther, 2014, 10(4):967-972.
21. Tolaney SM, Barry WT, Dang CT, et al.Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.N Engl J Med, 2015, 372(2):134-141.
22. Aboutorabi A, Hadian M, Ghaderi H, et al.Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early breast cancer.Glob J Health Sci, 2014, 7(1):37868.
23. 陳小松, 沈坤煒.曲妥珠單抗在HER2陽性乳腺癌治療中的共識與爭議.外科理論與實踐, 2011, 16(6):601-602.
24. Church DN, Modgil R, Guglani S, et al.Extended survival in women with brain metastases from HER-2 overexpressing breast cancer.Am J Clin Oncol, 2008, 31(3):250-254.
25. Eichler AF, Kuter I, Ryan P, et al.Survival in patients with brain metastases from breast cancer:the importance of HER-2 status.Cancer, 2008, 112(11):2359-2367.

Previous Article
肝間葉性錯構瘤1例報道
Next Article
Clinical Analysis of Lamivudine Combined with Low-Dose Hepatitis B Immune Globulin to Prevent HBV Reinfection after Liver Transplantation

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Curative Effects Observation of Capecitabine and Hessaitin Combined with Whole Brain Radiotherapy for Treatment The HER2 Positive Breast Cancer with Brain Metastasis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content